Remember, one of the common arguments of the tort reform crowd is that trial lawyers keep drugs from coming to market. If pharmaceuticals were really concerned about people having access to drugs, would they be doing this?
WASHINGTON—The Federal Trade Commission expressed concern about the practices of brand-name drug makers after generic drug companies complained they can’t get bulk supplies of some medicines they want to copy.
GlaxoSmithKline PLC and Celgene Corp. are among the brand-name makers citing a federal drug-safety program in declining at this point to supply bulk quantities of certain drugs. They say the generic companies aren’t authorized to buy drugs under the program. The generic companies say that’s an excuse to block competition.